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1. Introduction 
The therapeutic application of radioiodine 131I in postoperative ablation of the remaining 
thyroid tissue, as well as in the treatment of recidivism and/or local and remote metastases 
of differentiated thyroid carcinoma has been a part of the clinical practice for over 50 years. 
It is a regular segment of the standard therapeutic procedure in differentiated thyroid 
carcinoma treatment and it comes recommended by a number of authorities in the field 
(American Association of Clinical Endocrinologists/Associatione Medici Endocrinologi 
[AACE/AME], 2006; Cooper et al., 2006; Pacini et al., 2006; Society of Nuclear Medicine 
[SNM], 2006, British Thyroid Association [BTA], 2007; Dietlein et al., 2007; Luster et al., 2008; 
National Comprehensive Cancer Network [NCCN], 2010;). Certain differences in opinion on 
the subject are concerned only with the dose that is applied, as well as with whether 
radioactive iodine therapy should be utilized in lower risk patients 
(ȃȐаțȖȤȘая&ШаțȠȩȞȪ, 1981; Haq et al., 2004; Ringel&Ladenson, 2004; Cooper et al., 2006; 
Pacini et al., 2006; Gheriani, 2006). Several decades of experience have shown indisputable 
beneficial effects of the administration of 131I as postoperative adjuvant therapy. However, 
there can be certain adverse effects, beside the beneficial ones, which are a consequence of 
radiation damage to other tissues and organs. The organs most exposed to the harmful 
radiation effect of 131I in differentiated thyroid carcinoma treatment are salivary glands, 
nasolacrimal ducts, stomach epithelium, kidneys, bladder wall, colon, gonads, bone 
marrow, etc. But, most long-term follow-up studies report a very low risk of secondary 
malignancies in long-term survivors (Rubino et al., 2003; Brown et al., 2008). Howewer, 
meta-analysis of two large multicenter studies showed that the risk of second malignancies 
was significantly increased relative to thyroid cancer survivors not treated with RAI (Sawka 
et al., 2009). The risk of secondary malignancies is dose related (Rubino et al., 2003), 
Cumulative 131I activities above 500–600 mCi are associated with a significant increase in 
risk. There appears to be an increased risk of breast cancer in women with thyroid cancer 
(Brown et al., 2003; Sandeep et al., 2006; Chen et al., 2001). It is unclear whether this is due to 
RAI therapy, screening bias or other factors.  
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The question that arises regarding radioactive iodine administration is: how do we optimize 
the beneficial therapeutic effects of radioiodine on one hand and minimize the adverse 
effects on other tissues and organs on the other. The compromise can be achieved in two 
ways. The first is to increase radioiodine uptake in thyroid tissue/tumour tissue and 
increasing the therapeutic efficiency of 131I. In other words, the aim is to achieve the best 
therapeutic effect in the target tissue with as low a dose of 131I as possible. The second is to 
reduce the adverse effects, i.e. reduce the amount of radiation energy 131I tissues by 
accelerating the elimination of radioiodine which hasn’t been bound by thyroid/tumour 
tissue.  
There is yet another reason why the accelerated elimination of radioiodine from the body of 
the patient should be striven for. The reason is legal and concerns regulations which exist in 
every country and which determine the amount of radioactive iodine that patients are 
allowed to have in their body without being required to receive their treatment in a 
‘restricted area’. With the doses of radioiodine normally applied in differentiated thyroid 
carcinoma treatment, hospitalisation of some duration is required in many countries. For 
this reason, it is in the best interest of the health system to shorten the hospitalisation, i.e. the 
isolation of the patient being treated with radioactive iodine, without reducing the 
therapeutic effect of 131I.  
There are significant variations in the regulations regarding 131I administration from one 
country to another. These variations mostly have to do with the upper limit of the 
radionuclide that can be administered without the patient requiring isolation. 
Legal regulations state that anything above that limit requires the therapy to be carried out 
on hospital premises, or more precisely, in special rooms designated as controlled radiation 
zones (‘restricted areas’). This limit varies in different countries. For example, in Serbia, the 
upper limit is relatively low and special precautions have to be taken if the radioactivity of 
131I exceeds 400 MBq (10.81mCi). In other words, the patient can be released from hospital 
only when the radioactivity in his body decreases below the level of 400 MBq (the Republic 
of Serbia, Ministry of environmental protection, 2003). The limit is significantly higher in the 
EU and USA, where hospitalisation is obligatory only if the  radioactivity of 131I exceeds 
1110 MBq (30mCi) (1110 MBq). In this case the patient is hospitalised and kept in isolation 
until their radioactivity level decreases to 30 mCi (1110 MBq) (Tuttle et al., 2000; Society of 
Nuclear Medicine [SNM], 2006). 
In cases of differentiated thyroid carcinoma treatment the doses of 131I vary from 30mCi for 
the remaining thyroid tissue ablation, to 200 mCi for the treatment of metastases, even 
though there are several records of the doses reaching as much as 333 mCi (9GBq) (Haq et 
al., 2004). With the application of these larger doses, the permitted radioactivity limit in the 
body is reached a few days following the application of the ablation/therapeutic dose of 131I 
(Venencia et al., 2002). The time necessary to reach the limit depends primarily on the dose 
applied and the condition of kidney function, as well as on the size of the thyroid/tumour 
tissue being treated. 
2. Methods for increasing radioiodine uptake 
2.1 Thyrotropin stimulation (endogenous and exogenous TSH stimulation) 
In order to optimize radioiodine uptake in the thyroid remnant or in thyroid tumour tissue, 
it is necessary either for the patient to have substantially elevated endogenous thyroid-
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stimulating hormone levels (serum TSH concentration above 30 mIU/mL), or to perform 
exogenous TSH stimulation by applying  recombinant human TSH (rhTSH).  
In the first case, sufficient levels of TSH are most commonly achieved if the patient is left 
without thyroid hormone replacement therapy for 4 to 6 weeks. The primary problem that  
frequently arises from thyroid hormone withdrawal as a way of increasing TSH levels is 
clinically evident hypothyroidism, which some patients find quite disagreeable. The 
condition is notable for hypometabolism, constipation, increased cholesterol levels in blood, 
the risk of cardiovascular disorders, and the most severe one – myxedema. 
In the second case, exogenous TSH stimulation of the uptake is achieved by the application 
of rhTSH, available on the market as Thyrogen® (Genzyme). This medication is given to the 
patient intramuscularly for 2 days, in 0.9 mg doses.  
Exogenous stimulation of thyroid minimises the chances of hypothyroidism, and at the 
same time enables better planning of radioiodine therapy. However, the application of rTSH 
increases the cost of the treatment significantly, as this medication is relatively expensive. 
The results of a number of studies have shown that the final effects of uptake stimulation, 
both with endogenous TSH, and exogenous rhTSH are equally satisfactory and thus both 
come equally recommended (Haugen et al., 1999; Pacini et al., 2006).  
2.2 Low iodine diet 
In order to achieve a better uptake in thyroid/tumour tissue, a low iodine diet is 
recommended, i.e. the daily intake of not more than 25-75 μg of iodine. Patients should be 
put on the diet for 10 to 30 days prior to the diagnostic or therapeutic application of 131I 
(Maxon et al., 1983; SNM, 2006; Thyroid Cancer Survivors' Association, 2007). 
The consequence of the low intake of iodine is iodine depletion in the body, which should 
result in its increased uptake in thyroid remnants/tumour tissue. Since most countries have 
legal regulations by which producers are obliged to iodise table salt, this low iodine diet 
practically presupposes the limitation of table salt intake, which usually proves to be difficult 
for the patients to put into practice. One teaspoon of iodised table salt contains about 400 
micrograms of iodine. Sea salt is also not recommended due to the fact that it contains a 
significant amount of iodine. The alternative is uniodised salt, which is often difficult to find. 
Apart from the limitation on table salt, it is essential that the patients avoid foods with high 
concentration of iodine (above 20 micrograms per meal), and these are the following: 
 seafood (fish, shellfish, seaweed, seaweed tablets, kelp). These are all very high in 
iodine and should be avoided. Food containing sea-based additives, such as   
carrageenan, agar-agar, algin, alginate and nori should also be avoided.  
 milk and dairy products such as cheese, cream, yogurt, butter, ice cream, milk 
chocolate, powdered dairy creamers, whey, casein and others which  contain significant 
amounts of iodine  (250 ml of milk- 1 cup or 16 tablespoons, contain from 88 to 168 
micrograms of iodine, or an average of 115 micrograms).  
 egg yolks or whole eggs 
 bread and pastry 
 salty processed foods such as potato chips and cured and corned foods such as hot 
dogs, ham, corned beef, sauerkraut, bacon, sausage, and salami. 
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 soybeans and most soy products (soy sauce, soy milk, tofu)  
 red, orange, or brown processed food, pills and capsules, because the artificial colour 
(erythrosine) used for these foods contains significant amounts of iodine   
 iodine-containing vitamins and food supplements 
A limited daily intake of food which contains moderate amounts of iodine (5-20 micrograms 
per meal) is recommended. This includes the following:   
 fresh meats (meat contains 56-290 micrograms of iodine per kilogram). Up to 140 grams 
a day of fresh meats such as chicken, beef, pork, lamb, and veal are fine on the low-
iodine diet.  
 grains, cereals. Up to 4 servings per day of grains, cereals, pasta, and breads without 
iodine-containing ingredients are fine for this diet. Homemade baked goods and cereals 
are best for this diet.  
 rices. Similar to grains, rices vary in the amount of iodine depending on the region 
where they are grown, so rice should be eaten only in limited amounts. Some low-
iodine diets recommend avoiding rice.  
These instructions can often pose a problem because some guidelines only say that certain 
items or certain food categories should be avoided, and do not give details within 
categories, or else they just give lists of foods and ingredients that are allowed, without 
limits on quantities consumed. 
Even though most recommendations and guides list iodine diet as an essential part of the 
preparation for radioiodine therapy application due to the fact that it increases the binding 
of iodine in thyroid/tumour tissue, there are also other, contrasting data. Some researches 
have shown that the effects of low iodine diet can include an increased iodine retention, 
instead of iodine depletion, especially if it is combined with the application of diuretics 
(Hamburger, 1969; Norfray & Quinn, 1974; Tepmongkol, 2002, Matovic et al. 2009a).  
2.3 Lithium 
The inhibiting effects of lithium carbonate on the release of iodine from the thyroid tissue 
are also useful in radioiodine treatment of differentiated thyroid carcinoma, for the purpose 
of achieving prolonged and increased radioiodine retention in the thyroid/tumour tissue 
(Briere et al., 1974; Gershengorn et al., 1976; Rasmusson et al., 1983; Pons et al., 1987). 
Researchers agree that the administration of 0.8-1.2 mmol/L of lithium carbonate results in 
an increased uptake and prolonged retention of radioiodine in thyroid/tumour tissue, 
which doubles the dose absorbed, without significant adverse whole-body irradiation. 
However, the majority of authors urge caution in using this medicine and suggest careful 
monitoring of its levels in plasma for the purpose of avoiding adverse effects, primarily 
intoxication, which affects the central nervous system and kidneys, and can potentially be 
fatal (Simard et al., 1989). 
2.4 Retinoids and an increasing expression of NaI symporter system 
Better accumulation of 131I into the remnant thyroid/tumour tissue can be achieved through 
an increased expression of genes that enhance the synthesis of the NaI symporter. Retinoids 
or their metabolites, which bind with retinoic A and X receptors (RAR and RXR), are known 
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to result in an increased expression of genes which lead to an increased synthesis of NaI 
symporters. This will theoretically lead to increased iodine uptake in thyroid/tumour tissue. 
However, there are contradictory data concerning the efficiency of this sort of adjuvant 
therapy in thyroid iodine uptake. While some researchers (Van Herle et al., 1990; Grunwald 
et al., 1998; Koerber et al., 1999) point out that the administration of 13-cis retinoic acid (in 
Accutan, Roche Laboratories, Nutley, NJ, USA) prior to radioiodine application increases its 
uptake in the tumour tissue, especially in follicular carcinomas, others (Gruning et al., 2003) 
do not find a significant efficiency in the increase of thyroid iodine uptake, based on studies 
of large groups of subjects. 
However, the latest findings on NaI symporter system expression, as well as the identification 
of genes which encode its synthesis (Mandell et al., 1999;  Spitzweg et al., 2001; Castro et al., 
2001; Chung et al., 2002; Kogai et al., 2006) will probably allow for new approaches in 
radioiodine therapy of differentiated thyroid carcinomas, that focus on the optimisation of the 
dose administered to patients, by increasing the efficiency of this therapy. 
3. Methods for increasing unbound iodine excretion  
3.1 Hydration 
The relevant literature suggests that the accelerated urinary excretion of 131I can be achieved 
by extensive hydration. However, there are also data that do not support this. For example, 
Giebisch et al. (Giebisch et al., 1956) concluded in their research on dogs that water diuresis 
does not induce iodine diuresis, as 95% of the filtered iodine gets reabsorbed by the tubules 
in proximity to water absorption spots. Even so, extensive hydration is recommended in 
patients receiving radioiodine therapy, since it can lead to the dilution of radioiodine in the 
urine and a decrease in radioactive iodine retention in the urinary tract, which contributes to 
the decrease in the dose absorbed by the urinary bladder wall and surrounding organs.  
3.2 Laxatives 
In order to accelerate elimination of 131I through stool, some experts prescribe laxatives to 
expedite bowel evacuation, especially in patients with constipation. Others, however, hold 
the opinion that only a small, insignificant amount of the applied radioiodine is eliminated 
in this way, and that therefore laxatives are not of great importance (Hays, 1993). For these 
reasons, it is considered that the administration of laxatives is not necessary in patients who 
have at least one stool a day. 
3.3 rhTSH (Thyrogen®) 
There are data that renal radioiodine excretion is ~50% faster during euthyroidism versus 
hypothyroidism due to reduced renal function in hypothyroidism. Administration of rhTSH 
minimises the chances of hypothyroidism and could be indirectly useful in accelerating of 
unbound radioiodine elimination. Howewer, based on their meta anlaysis study, 
Freudenberg and co-workers (Freudenberg et al., 2010) suggests (but without statistically 
significant evidence), that rhTSH administration may results in a lower radiation dose to 
DTC metastases than does thyroid hormone withdrawal (THW). Furher studies should 
resolve this issue. 
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3.4 Diuretics 
For the purpose of reducing the absorbed dose in critical organs and tissues of patients 
treated with radioiodine, a simple and efficient method is often recommended for the 
excretion of unbound 131I – extensive hydration in combination with additional diuretic 
therapy. 
In a study conducted on 49 adult subjects with and without thyroid and kidney function 
impairment, Bricker and Hlad (Bricker&Hlad, 1955) concluded that 131I gets excreted from 
the body by means of passive filtration in glomeruli and gets partially reabsorbed by the 
tubuli by means of passive back-diffusion, without any active tubular transport 
mechanisms. 
There are various, often contradictory data in the literature concerning the effects of 
diuretics on the biokinetics of radioiodine elimination. The majority of studies point to the 
fact that faster elimination of radioiodine can be achieved by the addition of diuretic therapy 
(Russell&Ingbar, 1965; Fregly&Gennaro, 1965; Fregly, 1966; McCarthy et al., 1967; Fregly& 
McCarthy, 1973; Seabold et al., 1993; Kapucu et al., 2003), but the results of other studies 
show that the administration of diuretics leads to increased radioiodine uptake in the 
thyroid tissue  (Hamburger, 1969; Norfray&Quinn,  1974; Ding et al., 2004; Tepmongkol, 
2002). The data concerning the studies of the urinary excretion of iodine and the effects of 
diuretics on its urinary excretion published so far are contradictory. They do not present a 
clear picture of what kind of benefits, if any, can be gained by adding diuretic therapy to 
radioactive iodine treatment protocols. This is probably at least in part due to the fact that 
the published data were obtained either from studies performed on animals 
(Fregly&Gennaro, 1965; Fregly, 1966; McCarthy et al., 1967), or from studies on patients who 
did not suffer from differentiated thyroid carcinoma and had not been operated on 
previously, and who received radioiodine doses far smaller than those given to patients 
suffering from differentiated thyroid carcinoma (Russell&Ingbar 1965; Fregly&McCarthy, 
1973; Tepmongkol, 2002; Kapucu 2003).  
There have been a small number of studies on the effects of diuretics on radioiodine 
clearance in patients who were treated with therapeutic doses of 131I, but the conditions 
under which these studies were conducted were to a certain degree different to the ones 
typical for clinical practice and the way this therapy is normally carried out (Maruca et al., 
1984; Seabold et al., 1993; Ding et al.,  2004). 
The effects of furosemide, hydrochlorotiazide, manitol, ethacrynic acid and acetozolamide 
on radioiodine urinary excretion have been studied so far. Out of all the diuretics, 
furosemide has been studied most. 
3.4.1 Furosemide 
Furosemide is effective, cheap and widely used. Abbott and associates (Abbott et al., 2008) 
have analysed the data concerning the effects of furosemide from both the medical and 
veterinary literature. Based on a considerable number of analysed papers, they concluded 
that one of the chief effects of furosemide includes iodine depletion in the body, which is 
achieved through a decrease in its reabsorption  in the thick ascending limb of Henle’s loop. 
Furosemide acts as the inhibitor of  Na-K-Cl cotransporter 2 (NKCC 2), which is the 
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mechanism present in the majority of other diuretics, excluding spironolactone. The 
inhibition of co-transporter NKCC 2 is dose-dependent with respect to the concentration of 
furosemide in the lumen, rather than in plasma. The administration of furosemide brings 
about an increase in sodium, chloride and water in distal collecting ducts, resulting in 
increased renal excretion of potassium and hydrogen. This can result in some patients 
developing hypokalemic and hypochloremic alkalosis, which is the most common adverse 
effects of this diuretic. For the purpose of hypokalemic and hypochloremic alcalosis 
prevention, it is advised that patients receive potassium chloride together with furosemide 
in cases of long term therapy.  
When it comes to the influence of furosemide on radioiodine excretion, numerous and often 
contradictory data have been published. Some of them point to the fact that this diuretic 
influences the acceleration of iodine urinary excretion leading to iodine depletion. However, 
in one of our previous studies (Matovic et al., 2009a) it has been unmistakably shown that 
this diuretic, in combination with low iodine diet, slows down the elimination of 
radioiodine in patients treated with this radionuclide (figure 1. and  figure 2.).  
 
Fig. 1. Urinary excretion of radioiodine in patients treated with furosemide (■), and in the 
control group patients().  
Our results were somewhat similar to the ones obtained by Maruca et al. (Maruca et al., 
1984), who concluded that diuretic-mediated iodide depletion is not universally successful 
and that it is far less effective than it was considered before, therefore casting some doubt on 
its clinical benefits. Their aim was to achieve iodine depletion with low iodine diet and 
diuretics (Hydrochlorotiazide and Furosemide) in patients who had previously undergone 
thyroidectomy due to differentiated thyroid carcinoma. The results they obtained point to 
the fact that this low iodine diet and diuretics increase the uptake of iodine in the tumour 
tissue. According to their findings, the total iodine uptake and retention in the tumour tissue 
was mostly the consequence of total body retention, and not some specific mechanism at the 
cell level of thyroid/tumour tissue. 
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Fig. 2. Scintigrams obtained 72h post therapy with 3.70 GBq of 131I in patients with (left) and 
without (right) furosemide aditional therapy. Increased amount of radioiodine in thyroid 
rest in case of previous furosemide therapy. Both patients had similar thyroid rest (uptake of 
radioidine was about 2% in both patients). 
The presumption that low iodine diet plays an important role in how furosemide affects 
iodine biokinetics can be supported by the data obtained from a number of researchers, who 
found that furosemide and other diuretics cause an increase in iodine excretion in those 
patients who were not put on a prior low iodine diet. A comparison between a research by 
Seabold et al. (Seabold et al., 1993)  and Norfray and Quin (Norfray&Quinn, 1974) provide 
possible further evidence for this. Specifically, Seabold et al. found that in patients who had 
not been on a low iodine diet and who had received radioiodine ablation therapy, 
furosemide as an adjuvant therapy accelerated the excretion of radioactive iodine, which 
enabled those patients to spend far less time on the hospital premises. 
Based on experiments in animals, Norfray and Quinn found that intraperitoneal application 
of furosemide leads to an increased iodide excretion, which in turn results in a decrease in 
iodide pool in their bodies. The same authors found that supplemental iodide diet does not 
reduce this effect of furosemide, even though the thyroid radioiodine uptake increases in 
comparison to the control group under the influence of diuretic therapy, which reduces the 
iodide pool. This indirectly points to the fact that an uptake increase in thyroid/tumour 
tissue can be achieved by the administration of diuretics as well. However, they did not 
measure blood radioactivity, so the possibility that an increase in uptake under the influence 
of furosemide is at least in part a consequence of increased blood radioactivity, i.e. total 
body retention, instead of just an increase in the avidity of thyroid tissue for iodine cannot 
be excluded either. 
Other researchers (Hamburger, 1969;  Norfray&Quinn,  1974; Tepmongkol, 2002) also found 
that furosemide does not increase iodine excretion, but on the contrary, that it decreases it. 
According to the data provided by Kapucu and associates (Kapucu et al., 2003), the 
administration of Furosemide results in the loss of iodine from subjects’ bodies (iodine 
depletion). 
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They noticed that after a 5-day furosemide therapy a better penetration of iodine into the 
thyroid gland was noted in patients who had not previously been on a low iodine diet, than 
in those who had been on the diet for 14 days, without receiving furosemide. The authors 
think the explanation for this lies in the loss of sodium from extracellular fluid which is 
greater when furosemide is administered than when preceded by a low iodine diet alone. 
However, Russell and Ingbar (Russell&Ingbar, 1965) state that there is an intrathyroid, 
pituitary-independent mechanism of increasing thyroid function as an answer to the 
reduction in iodine concentration in plasma. As far back as 1965 they studied the effect of 
iodine depletion (with previous low iodine diet and the administration of manitol) on 131I 
biokinetics and thyroid function, on a group of 8 patients. 
According to their results, iodine depletion resulted in decreased iodine levels in blood, an 
increase in thyroid iodine transfer and the speed of thyroid clearance, as well as an increase 
in thyroid iodine uptake followed by a decrease in absolute iodine accumulation. These 
authors concluded within the same study that there is no increase in thyroid iodine 
clearance and 131I uptake if NaI is applied together with manitol. 
It should be stressed that in our research on mice (Matovic et al., 2009b) we did not note an 
increased radioiodine retention in thyroid tissue when we applied furosemide, even though 
they had undergone a low iodine diet. This can point to the fact that iodine biokinetics has 
certain species specific characteristics, either at the level of kidneys, or at the level of thyroid 
gland.  
In our research, which included patients treated with radioiodine, we did not determine 
whether there is an increase in thyroid/tumour tissue uptake under the influence of 
furosemide therapy, but our results indirectly support the data provided by Maruca et al. 
that in cases of increase the most likely reason is, up to a certain point, an increase in 131I 
levels in blood, i.e. an increase in total body retention of the radionuclide under the 
influence of additional furosemide therapy. 
An important role in this mechanism is played by the preceding low iodine diet, which can 
be concluded based on the data provided by Hamburger et al. (Hamburger et al., 1969). 
They determined the uptake in thyroid/tumour tissue in a group of 25 patients with a 
confirmed diagnosis of inoperable thyroid carcinoma, who had previously been treated with 
diuretics and a low iodine diet. What was achieved by a combination of a low iodine diet 
and diuretics (manitol and ethacrynic acid) was doubled, or even tripled uptake in 16 
patients, mild increase in 3, and no increase in 6 patients. According to their data, 
radioiodine levels in thyroid/tumour tissue remain high 96 hours following the diuretic 
preparation. 
3.4.2 Other diuretics 
Based on the results obtained from a controlled study, Tepmonkogol (Tepmongkol, 2002) 
concluded that the binding of radioiodine in the thyroid gland is as many as 7.18 times 
higher when hydrochlorothiazides were administered together with a low iodine diet. The 
control group comprised patients who were on a low iodine diet, but who received neither 
hydrochlorothiazide, nor other diuretics. The control group showed an increase in the 
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uptake as well, even though a significantly smaller one, amounting to 1.33 times the original 
binding. The study was performed on patients suffering from hyperthyroidism who had 
been treated with radioiodine. Similar results were obtained by Ding and his associates 
(Ding et al., 2004), who showed that the administration of hydrochlorothiazide prior to the 
dosing of radioiodine can significantly increase the dose absorbed by the thyroid tissue. The 
study included patients suffering from differentiated thyroid carcinoma who had previously 
undergone thyroidectomy. 
In a study performed on 18 young male subjects following an acute administration of 
hydrochlorothiazide and acetazolamide, Fregly and McCarthy (Fregly&McCarthy, 1973) 
analysed the fluctuations in urinary excretion of Na, K, Ca, Mg, Cl and I. Based on the 
results of this study, as well as on the previous studies done on animals (McCarthy et al., 
1967, Fregly, 1966,  Fregly&Gennaro, 1965), the authors concluded that hydrochlorothiazide 
has a significant effect on an increase in iodine excretion, which is closely tied to an increase 
in chloride excretion, while there was no increase in either iodine, or chloride excretion in 
those treated with acetazolamide. 
Judging by all the aforementioned data, the most probable cause of the decrease in 131I 
excretion under the influence of diuretics is the state of iodine depletion caused by the prior 
low iodine diet. For some reason this state is characterised by an absence of iodine 
reabsorption blockage in the tubuli under the influence of diuretic therapy, and 
paradoxically, results in increased iodine reabsorption. 
Walser and Rahill (Walser&Rahill, 1965) concluded that the reabsorption of iodine and 
chlorine is done in the same part of the nephron by means of passive diffusion with a 
constant ratio of tubular permeability. Since the low iodine diet was at the same time low 
chloride, as well as a low sodium diet (due to the reduced table salt intake), it is possible 
that the explanation for this unexpected and paradoxical effect of diuretics on radioiodine 
excretion lies in that very fact. 
Namely, it is possible that in cases where low iodine diet (i.e. low chloride/low sodium diet) 
was prescribed, the increase in the reabsorption of chlorine gets followed by an increase in 
iodine reabsorption at the level of the ascending segment of Henle’s loop and the proximal 
tubules. As a consequence, iodine excretion decreases, instead of increasing, and the same 
goes for its blood levels, which directly influenc the prolongation of patient hospitalisation 
in the restricted area after the application of radioiodine therapy, due to the maintenance of 
high circulating levels. For this reason it is not advisable to use additional diuretic therapy 
for the purpose of speeding up the urinary excretion of radioiodine, at least not in patients 
who had previously been on a low iodine diet. 
4. Methods for salivary glands and nasolacrimal ducts protection  
Some authors recommend measures to prevent damage of the salivary glands and 
nasolacrimal ducts. Damage of those organs results with transient loss of taste and excessive 
tearing (epiphora), as clinical compliications. Methods for prevention of those complications 
have included usage of amifostine, hydration, sour candies, and cholinergic agents 
(Mandal&Mandal, 2003). Howewer, in relevant literature there are not enough evidence to 
recommend for or against these methods. There are even authors (Nakada et al, 2005) who 
suggested sour candy may actually increase salivary gland damage. 
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5. Conclusion 
With the aim of achieving a satisfactory compromise between high therapeutic efficiency of 
radioiodine therapy on thyroid/tumour tissue and the need to decrease its adverse effects 
on other tissues and organs, it is necessary for the patient to be carefully selected and 
adequately prepared. 
The most basic part of the preparation is the achievement of high TSH stimulation in order 
to increase radioiodine uptake in the thyroid/tumour tissue. Both exogenous and 
endogenous methods of TSH stimulation are equally valid from the point of view of 
achieving the uptake, but keeping the patient without substitution for several weeks can be 
highly disagreeable, and in some patients even dangerous, due to the possible 
complications. On the other hand, the convenience that comes with the use of rhTSH comes 
at a higher cost. It is up to the patient and the physician to estimate which method of TSH 
stimulation to use by evaluating the cost/benefit of exogenous and endogenous TSH 
stimulation in each individual case. 
The low iodine diet comes right after TSH stimulation as the second most important step in 
the preparation of patients for radioiodine therapy, its purpose being to increase the 
radioiodine uptake in thyroid/tumour tissue. However, it should be borne in mind that 
there can be a possible interference of this diet with the potential use of diuretics in patients 
treated with radioiodine. In any case, it is indisputable that a low iodine diet helps achieve a 
higher radioiodine uptake in the thyroid/tumour tissue, and it should therefore be 
prescribed to patients who are to receive the radioiodine therapy. 
The administration of lithium is an efficient method of increasing the uptake of radioiodine 
in thyroid/tumour tissue, but it is not recommended in routine clinical practice, since its 
administration can have serious complications in case of an overdose. An increase in NaI 
symporter expression in thyroid/tumour tissue, achieved by the application of retinoids, 
results in a favorable increase in radioiodine uptake. Even though it does not belong to the 
clinical routine, this method can be useful in patients who have lost the ability to accumulate 
radioiodine in the tumour tissue. These patients are characterised by the secretion of 
thyroglobulin, a positive PET scan and a negative radioiodine scan. Further research on the 
identification of the gene responsible for the coding of NaI symporter system synthesis can 
provide a new approach to radioiodine treatment of thyroid carcinoma in the sense of dose 
optimisation, i.e. the prospects of increasing the efficiency of the therapy.  
When it comes to methods aimed at accelerating the excretion of radioiodine that has not 
been bound to the thyroid/tumour tissue, extensive hydration of the patients is 
recommended, as it reduces the absorption in the critical organs by diluting the urine and 
increasing urinary volume, even though it does not result in increased iodine excretion. 
Laxative administration in patients who have regular emptying of the bowel can cause 
certain discomfort to the patients, so this is not clinically justified nor necessary, having in 
mind the small quantity of radioiodine that gets eliminated in this way. 
In patients who had been on a low iodine diet there is a decrease in excretion of 131I under 
the influence of diuretics, which results in an increase in its levels in blood, which in turn 
indirectly prolongs the hospitalisation period. The patient has to be detained in the 
restricted area following the radioiodine therapy due to the high circulating levels that are 
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maintained in their bodies. All this also results in a higher dose being absorbed by the 
patient’s critical organs. For this reason, the administration of diuretics for the purpose of 
accelerating urinary excretion of radioiodine cannot be recommended, at least not in 
patients who had previously been on a low iodine diet. 
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